Drug Profile


Alternative Names: EPI-M13

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator EpiPharm AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Melanosis

Most Recent Events

  • 07 Jan 2016 EpiPharm plans a phase I/II trial for Melanosis
  • 07 Jan 2016 Preclinical development for Melanosis is ongoing in Switzerland
  • 01 Jan 2014 Preclinical trials in Melanosis in Switzerland (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top